BioSpace News Archive

AltPep Corporation today announced the completion of a $52.9 million Series B financing round.

Nuo Therapeutics, Inc., a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage, the nation’s leading wound care consulting firm has added the Aurix® System to its formulary.

BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia, B-Cell Lymphomas, Pediatric Acute Lymphoblastic Leukemia, and Pediatric Aggressive Mature B-Cell Lymphomas.

Aeglea BioTherapeutics, Inc. (“Aeglea”) (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. (“Spyre”), a privately held biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD).

Caristo Diagnostics Limited applauds the FDA’s decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease.

Jaguar Health, Inc. today announced that the Company is launching an AI-driven series of disease awareness educational content on social media regarding cancer therapy-related diarrhea in dogs and people.

Microbot Medical Inc. announced the expansion of its global IP portfolio by receiving a Grant of Protection from the Japan Patent Office for a Design Patent covering the innovative industrial design of the robotic drive of the LIBERTY Robotic Surgical System.

SELLAS Life Sciences Group, Inc. today announced that the first patient has been dosed in a Phase 2a study of its novel and highly selective CDK9 inhibitor, GFH009, in combination with venetoclax and azacitidine (aza/ven) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) who did not respond or stopped responding to venetoclax-based therapies.

Cancer and cardiovascular diseases (CVDs) continue to be two of the biggest challenges facing modern medicine.

Accumulus Synergy, a nonprofit trade association working to address the global need for digital transformation within the life sciences - regulatory ecosystem, announced the appointment of Jacques Mascaro as the new Chair of the Board of Directors.